Programmed cell death 1 receptor antibody - Boehringer Ingelheim
Alternative Names: PD-1 receptor antibody - Boehringer IngelheimLatest Information Update: 07 Jun 2024
At a glance
- Originator Boehringer Ingelheim
- Class Antibodies
- Mechanism of Action Programmed cell death 1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Immunological disorders
Most Recent Events
- 30 Apr 2024 Phase-I clinical trials in Immunological disorders (Parenteral) prior to April 2024 (Boehringer Ingelheim Pipeline, April 2024)